new glp 1 drugs in development GLP-1 Receptor Agonist Market Size & Analysis, 2026-2033 New oral glp-1 weight loss

This, in turn, stimulates downstream signaling elements dependent on both protein kinase A (PKA) and exchange protein directly activated by cAMP (EPAC) activation, which triggers the opening of voltage-dependent calcium channels (VDCCs), resulting in insulin exocytosis [24, 25]

Another GLP-1 Pill May Soon Be Available The Wegovy pill is not the only GLP-1 oral treatment expected in 2026

Cardiovascular Benefits Beyond shedding pounds, these drugs also support heart health

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) for the treatment of type 2 diabetes mellitus: friends or foes to bone health

ADA Recommendations for GLP-1 RA in T2DM Patients The GLP-1 receptor agonists, with or without metformin based on glycemic needs, are appropriate initial therapy for patients with type 2 diabetes mellitus (T2DM) with or at high risk for atherosclerotic cardiovascular disease (ASCVD)/indicators of high-risk, heart failure (HF), or chronic kidney disease (CKD)

Per publicly available announcements, the FDA issued more than 50 warning letters to GLP-1 compounders and manufacturers in September 2025, followed by 30 additional warning letters to telehealth firms in early 2026, targeting false or misleading marketing claims about compounded GLP-1 products